Cargando…
Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19
We report in vivo selection of a severe acute respiratory syndrome coronavirus 2 spike mutation (Q493R) conferring simultaneous resistance to bamlanivimab and etesivimab. This mutation was isolated from a patient who had coronavirus disease and was treated with these drugs.
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Centers for Disease Control and Prevention
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462334/ https://www.ncbi.nlm.nih.gov/pubmed/34314668 http://dx.doi.org/10.3201/eid2710.211538 |